LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Noninvasive Test Detects Malaria Without Blood Sample

By LabMedica International staff writers
Posted on 30 Oct 2024
Image: The Cytophone clinical prototype (Photo courtesy of Nat. Commun.; Yadem, A.C., Armstrong, J.N., Sarimollaoglu, M. et al.)
Image: The Cytophone clinical prototype (Photo courtesy of Nat. Commun.; Yadem, A.C., Armstrong, J.N., Sarimollaoglu, M. et al.)

Malaria remains a significant global health issue, with approximately 250 million cases and over 600,000 deaths reported annually. Nearly half of the world's population is at risk for malaria infection, particularly vulnerable groups such as children and pregnant women, who face the highest likelihood of severe illness and death from the disease. Currently, detecting this potentially fatal infection typically requires invasive blood samples, and existing testing methods have considerable limitations that hamper their effectiveness. A new technology now presents an exciting point-of-care (POC) diagnostic tool that has the potential to improve malaria detection and facilitate timely treatment.

Researchers at Yale School of Public Health (New Haven, CT, USA) and their collaborators have introduced a novel noninvasive test that could significantly transform malaria testing in low- and middle-income countries that are heavily impacted by this mosquito-borne illness. The innovative test does not require any blood samples, making it safer and more accessible. It utilizes a device called the Cytophone, which employs targeted lasers and ultrasound to identify malaria-infected cells in the bloodstream. Roughly the size of a tabletop printer, the Cytophone prototype can quickly ascertain the presence of malaria infection through a small, noninvasive probe applied to the back of a patient’s hand over a targeted vein.

The Cytophone's ability to detect infections noninvasively is made possible due to the accumulation of a by-product known as hemozoin in red blood cells infected with malaria parasites. This iron crystal by-product absorbs more light than normal hemoglobin when exposed to laser light, heating up and displaying magnetic and optical properties that the Cytophone probe can identify. In research published in Nature Communications, the team evaluated the Cytophone on 20 adult patients diagnosed with symptomatic malaria in Cameroon. The device successfully identified Plasmodium falciparum, the most prevalent and lethal malaria parasite, along with other less common species. The findings demonstrated that the Cytophone is sensitive enough to detect both high and low levels of parasites in infected blood, achieving 90% sensitivity and 69% specificity—comparable to, and in some cases exceeding, current gold standards for malaria testing that necessitate blood draws. Additionally, the device was capable of tracking the reduction of parasite levels when patients were retested post-treatment.

“Our study showed that the Cytophone was safe and had comparable diagnostic performance to current point-of-care options when compared to highly sensitive quantitative PCR as the gold standard,” said Jillian N. Armstrong, one of the study’s lead authors.

Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
Rapid Sepsis Test
SeptiCyte RAPID

Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
ADLM